Checked Nov 5, 2026Start a new check

What was checked

Do NOT take the new FDA approved mFLUSIVA mRNA flu shot: 75.7% reported adverse reactions within 7 days, severe systemic reactions 5-6X higher (1 in 20), 102 deaths in trial (called unrelated with no autopsies), only 6-month follow-up, same platform as COVID shots with no true saline placebo.

Assessment summary

Needs caution

This contains some claims that could not be fully verified or may be partially inaccurate. All assessments reached the same verdict.

Key findings

Model assessments

Assessment summary

  • The claim mixes some real trial facts with unsupported or misleading conclusions.
  • FDA materials report 102 deaths among mRNA-1010 recipients over the full study period, but also report a similar comparator-group rate and do not support the claim that there were no autopsies; the available evidence does not establish that the vaccine caused those deaths.fda.gov nctr-crs.fda.gov FDA documents describe approximately six months of follow-up and an active-control design, while the cited materials do not substantiate the 75.7%, five-to-six-fold, or “no true saline placebo” claims as presented.nctr-crs.fda.gov fda.gov

Claims reviewed

The 102 deaths were called unrelated to vaccination.

Needs context
The number of deaths is reported, but the available FDA summary also reports 97 deaths in the comparator group and does not establish that every death was individually proven unrelated.nctr-crs.fda.gov

This claim may mislead readers without added context.

The trial had only six months of follow-up.

Needs context
FDA documents describe approximately six months of median follow-up in key safety studies, but the full study period included longer or otherwise specified follow-up reporting; “only” overstates the evidence.nctr-crs.fda.gov fda.gov

This claim may mislead readers without added context.

MFLUSIVA uses the same platform as COVID shots.

Can’t verify
MFLUSIVA is an mRNA vaccine, but the sources reviewed do not establish that it uses the same formulation, construct, or manufacturing platform as specific COVID-19 vaccines.

Assessment summary

  • The claim contains some factually accurate statistics (75.7% adverse reactions, Grade 3 systemic reactions 5-6X higher, 102 deaths, 6-month follow-up) that match published trial data and independent reanalysis.
  • However, critical context is omitted or misrepresented: the adverse reactions were mostly mild-to-moderate and resolved within 2 days; the deaths were not definitively attributed to the vaccine by FDA reviewers; and the claim lacks important nuance about the comparator used and the vaccine's modest efficacy benefit.

Claims reviewed

called unrelated with no autopsies

Needs context
FDA documents state 'No autopsies were conducted in the mRNA-1010 group deaths' fda.gov. However, FDA reviewers concluded the temporal distribution of deaths 'does not suggest definitively indicative of a safety concern' fda.gov. The claim oversimplifies by suggesting deaths were dismissed; independent reanalysis identified a potential mortality signal (23-29 unexplained deaths vs 9-12 in comparator) zenodo.org fda.gov.

This claim may mislead readers without added context.

severe systemic reactions 5-6X higher (1 in 20)

Supported
Grade 3 systemic reactions occurred in 5.5% of mFLUSIVA recipients versus 0.9% of standard-dose comparator (RR 6.15), and 4-fold higher versus high-dose comparator (RR 4.08) journalofindependentmedicine.org zenodo.org. This matches the '5-6X higher' claim.

75.7% reported adverse reactions within 7 days

Supported
Multiple sources confirm 75.7% of mFLUSIVA recipients reported solicited adverse reactions versus 46.7% of comparator recipients over 7 days of follow-up journalofindependentmedicine.org zenodo.org fda.gov.

Assessment summary

  • Some numerical claims are accurate and supported by FDA clinical documents.
  • Other assertions mix accurate facts with misleading or unverified statements (notably about deaths and autopsies).
  • Overall the passage contains both true and unverified/misleading elements, so a mixed verdict is appropriate.

Claims reviewed

102 deaths in trial (called unrelated with no autopsies)

Needs context
FDA data show 102 deaths among mRNA-1010 recipients across the integrated safety set (all-cause mortality 102 vs 97), but the FDA reviewed narratives and did not attribute a causal link; the assertion that there were 'no autopsies' is unverified in the public documents. The statement mixes confirmed death counts with an unverified claim about autopsies and intent. fda.gov fda.gov

This claim may mislead readers without added context.

Severe systemic reactions 5-6X higher (1 in 20)

Supported
The FDA report shows Grade 3 solicited systemic adverse reactions were 5.5% in MFLUSIVA versus 0.9% in the standard-dose comparator, about a 6-fold difference (≈1 in 20). fda.gov

Only 6-month follow-up

Supported
The FDA summary shows median follow-up in the principal safety studies was about 184 days (≈6 months) for Study P304 and 171 days for P303 Part C. fda.gov

Sources cited

17 sources

Share this result